STAT+: In wake of boy’s death, gene editing experts dissect Huidagene’s decisions

A young boy died last year in a gene editing clinical trial run by Huidagene, and now experts in the field are scrutinizing the decisions the company made in designing and executing that study, according to STAT News.

Three months before the boy's death, Huidagene's former CEO Alvin Luk presented the company's early trial data at the American Society for Gene and Cell Therapy's Presidential Symposium, per STAT News. STAT subsequently asked several specialists in gene editing and muscle disorders to review video of that presentation. Their assessments were divided. "I'm not impressed," Dongsheng Duan, a researcher who has spent a decade studying gene editing for Duchenne muscular dystrophy at the University of Missouri, told STAT by email.

The trial targeted Duchenne muscular dystrophy using a gene editing strategy that U.S. companies have largely abandoned, according to STAT News. Experts questioned the technical modifications Huidagene applied in attempting to improve on that approach. The company's decisions — what to try, how to implement it, and when to move into human patients — are now under examination in the wake of the fatality.

Huidagene's trial death was first reported by STAT News in early August 2026, in a piece that also raised broader safety questions about investigator-led studies in China. The current story extends that coverage by bringing in outside scientific voices to assess whether the underlying study design and science met the field's standards.

The full expert analysis, including where reviewers agreed and where they diverged sharply on the quality of Huidagene's science, is available to STAT+ subscribers. What the publicly available summary makes clear is that the company's approach was neither universally condemned nor endorsed — reflecting ongoing uncertainty in the gene editing field about how far experimental strategies should be pushed before entering human trials.